abacavir (Ziagen)

10/01/2010 - "Abacavir (ABC) is an antiretroviral drug highly effective in the treatment of HIV, but its intake can cause severe hypersensitivity reaction (HSR). "
05/01/2006 - "The strong association between HLA-B5701 and abacavir hypersensitivity reaction shows promise for a genetic screening test to be feasibly incorporated into clinical practice. "
04/01/2010 - "Recent success in developing clinically useful genetic tests that have allowed us to predict the risk of abacavir-induced hypersensitivity has helped to pave the path for a pharmacogenetic approach. "
11/01/2011 - "The present study discusses the issues of patch testing associated with pharmacogenetic screening in light of the development of abacavir hypersensitivity reactions (HSRs). "
06/01/2011 - "Among 1150 African children receiving antiretroviral therapy in a randomized trial, suspected hypersensitivity reactions to abacavir were rare (0.3%; 95% CI, 0.01-0.9). "

01/01/2015 - "The use of abacavir has been linked with increased cardiovascular risk in patients with human immunodeficiency virus infection; however, the mechanism involved remains unclear. "
12/01/2006 - "Abacavir/lamividune combination in the treatment of HIV-1 infection: a review."
03/01/2004 - "Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. "
10/15/2011 - "Current or recent use of abacavir for treating human immunodeficiency virus type 1 (HIV-1) infection has been associated with increased rates of myocardial infarction (MI). "
06/12/2006 - "As in chronic infection, HLA-B5701 is associated with the abacavir hypersensitivity reaction in PHI. "

09/01/1997 - "AIDS activists and Glaxo Wellcome are clashing over the manufacture and use of a new and potent nucleoside analog, 1592 (abacavir), that shows strong promise in effectively treating AIDS. "
01/01/2012 - "Among the Study to Understand the Natural History of HIV/AIDS in the Era of Effective therapy (SUN) participants, we identified 25 individuals (cases) who were HLA-B5701-negative and who had ≥ 2 weeks without abacavir exposure at one visit and ≥ 2 weeks with abacavir exposure at the consecutive visit while maintaining viral suppression. "
05/01/2011 - "Banked sera from entry and week 96 visits of AIDS Clinical Trials Group A5095 participants were assayed for hsCRP, then analyzed by gender, abacavir randomization, and for correlation with changes in fasting metabolic parameters. "
04/01/2011 - "We analyzed data from 5056 individuals initiating randomized antiretroviral treatment (ART) in AIDS Clinical Trials Group studies; 1704 started abacavir therapy. "
02/28/2006 - "The Pediatric AIDS Clinical Trials Group P1026s study is an on-going, prospective, non-blinded pharmacokinetic study of pregnant women receiving one or more antiretroviral drugs for routine clinical care, including a cohort receiving abacavir 300 mg twice daily. "

09/01/2001 - "The results of this animal study indicate that abacavir would be a useful addition to a treatment regimen against HIV-infection within the brain."
11/15/1996 - "Two HIV infection trials involving an experimental nucleoside, called 1592U89 or 1592, are recruiting patients. "
11/01/2012 - "In multivariable analysis, older age, longer duration of HIV infection, and current abacavir use were associated with lower FMD. "
04/01/2012 - "Abacavir is used to treat HIV infection in both adults and children. "
07/15/2011 - "The application of this methodology is a rapid and simple method to detect the HCP5 polymorphism (rs2395029) previous to administration of Abacavir in patients with HIV infection."

01/01/2007 - "Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial."
12/01/2006 - "Abacavir (ABC) achieves good CSF concentrations and studies of high-dose ABC showed benefit in adults with HIV dementia. "
11/07/1997 - "Glaxo Wellcome is broadening the entry criteria for its experimental antiretroviral drug 1592 (abacavir) for persons with AIDS dementia complex (ADC). "
04/13/2001 - "HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir."
01/01/2007 - "To determine the efficacy of adding abacavir (Ziagen, ABC) to optimal stable background antiretroviral therapy (SBG) to AIDS dementia complex (ADC) patients and address trial design. "